Adolescent major depressive disorder (MDD) is common worldwide and affects 8--20% of all youth ([@b30]; [@b32]). The onset of puberty, especially in girls, is marked by a major increase in prevalence ([@b52]). Moreover, MDD and anxiety disorders (AD) are frequently comorbid in adolescents ([@b2]) with estimated comorbidity rates of 75% ([@b33]). While this comorbidity may be explained in part by common variance between anxiety and depression assessment tools ([@b1]), both MDD and AD reflect clinically important levels of subjective distress and negative affect ([@b59]).

Adolescents with depression are at higher risk of many negative health outcomes including increased risk of suicide, substance use disorder ([@b9]), and physical illnesses such as cardiovascular disease, Type II diabetes, metabolic syndrome, and pathological cognitive aging ([@b41]; [@b61]). Various mechanisms have been proposed to explain the association between depression and systemic disease, such as the glucocorticoid cascade ([@b36]) and an increased allostatic load ([@b28]; [@b40]).

We and others have also shown that vagal inhibitory tone, which is associated with autonomic self-regulation, is decreased in adolescents and adults with anxiety disorders and depression, indicating an impairment of the descending vagal pathways in these disorders ([@b25]; [@b35]; [@b47]; [@b53]). Conversely, increased influence of the myelinated vagus decreases the HR, inhibits fight and flight activity, decreases the hypothalamic-pituitary-adrenal axis response, inflammatory processes, and glucose regulation, and promotes social behavior ([@b45]; [@b54]). The output from the prefrontal cortex and amygdala are under vagal inhibitory control by the myelinated vagus nerve. The high frequency domain of heart rate variability (HRV) includes the respiratory sinus arrhythmia (i.e., the variability of heart rate that is synchronized with the breathing rate). The high frequency domain of HRV is thought to best capture the vagal tone ([@b8]; [@b38]).

Respiratory patterns have been studied in relation to emotional disorders and are known to affect vagal tone. It has been debated whether hyperventilation is a response to perceived chronic stress and whether this respiratory pattern may sustain or even contribute to the allostatic load and the symptomatology of anxiety and depression ([@b5]; [@b15]; [@b23]; [@b39]). When breathing pattern changes in parallel with changes in metabolic activity, such as during exercise, sleep, or fever, circulating blood gases show little or no change. However, when psychological influences change breathing pattern in the absence of changes in metabolic activity, as may be the case in anxiety and depressed patients, blood gases do change. Hyperventilatory breathing during anxiety or emotional distress decreases partial pressure CO~2~ (pCO~2~, hypocapnia; [@b43]), The decrease in pCO~2~ associated with hyperventilatory breathing results in respiratory alkalosis, as indicated by a decrease of end-tidal CO~2~ (ETCO~2~; the peak concentration of carbon dioxide at the end of the expiratory phase of a breath. ETCO~2~ is considered proportional to the arterial pH; [@b17]). Hyperventilatory breathing and the resulting decreases in ETCO~2~ can be achieved by increasing breathing rate, breathing volume, rapid shallow breathing, or a combination of these patterns ([@b34]). Thus, while many often focus on respiratory rate (RR), this is only one of the factors contributing to decreases in ETCO~2~.

Research in the field of respiratory psychophysiology, as well as several Eastern traditions, claims that emotional states are expressed in breathing patterns, and that voluntary change of breathing patterns can alter emotional states ([@b11]; [@b12]; [@b13]; [@b21]; [@b37]; [@b55]; [@b57]). It is well known that acute hypocapnia can produce adverse physiological and medical effects and induce symptoms of anxiety and panic ([@b21]; [@b34]), but the concept of a chronic hyperventilation syndrome is debated and currently lacks conclusive diagnostic criteria ([@b5]; [@b15]). Studies based on self-assessment in pediatric and adolescent populations indicate a high prevalence of hyperventilation ([@b4]; [@b20]). A long-term follow-up study of children and adolescents with hyperventilation showed that 40% were still hyperventilating as adults, and many had signs and symptoms of chronic anxiety ([@b26]). Despite these findings, whether breathing patterns and respiratory metabolism contribute to emotional dysregulation and the disease progression of anxiety and depression in adolescents is not established.

The primary aim of this study is to determine whether adolescent girls with emotional disorders show more hyperventilation, measured by ETCO~2~ and RR, than healthy controls, and whether ETCO~2~ and RR can be used to distinguish between the two groups. We hypothesize that adolescent girls with emotional disorders will have lower ETCO~2~ and higher RR than healthy controls, which would imply that breathing-based interventions may constitute a target for the development of new treatment models.

Secondary aims of the study are to investigate (a) the relationship between emotional symptom severity and respiratory parameters, (b) the relationship between respiratory parameters (RR and ETCO~2~) and autonomic regulation as measured by HRV, and (c) possible differences in RR and ETCO~2~ between subjects in the clinical group with and without antidepressive medication (selective serotonin reuptake inhibitors; SSRIs). Adolescent girls with MDD and/or AD were included in the clinical sample due to the previously described high comorbidity rates.

Method
======

Description of the Samples
--------------------------

A detailed description of the samples and the data collection procedures has been published in previous papers in which respiratory patterns were not analyzed ([@b24]; [@b25]). In summary, the original clinical sample consisted of adolescent girls (*n* = 79) with a mean age of 16.8 years (range: 14.5--18.4 years) who were psychiatric patients and had a Development and Wellbeing Assessment (DAWBA, see below) validated clinical diagnosis of MDD and/or one or several ADs (general anxiety disorder, social phobia, specific phobia, panic disorder, separation anxiety, posttraumatic stress disorder) at the time of assessment. The subjects had on-going treatments (median duration of 11 months) at one of 13 open psychiatric clinics for children and adolescents located in the center of Stockholm, surrounding suburbs, or in smaller towns nearby. Patients with severe autism or psychotic symptoms were not recruited to the study. Six subjects were denied participation because the DAWBA was incomplete or could not confirm diagnoses of MDD and/or AD. All measurements were performed at the patient\'s clinic by the first author and an assistant and followed the same order in all subjects.

The original control sample consisted of adolescent girls (*n* = 66), with a mean age of 16.5 years (range: 15.9--17.7 years) recruited from four different high schools. The clinical patient sample and the controls were age matched and recruited from similar locations in and around Stockholm. The measurements of the control sample were carried out at the school nurses\' offices by the first author and four nurses. Exclusion criteria for both samples were diabetes, thyroid dysfunction, pregnancy, and more than 5% missing or distorted data in any registered data segment. The exclusion procedure is described in Figure [1](#fig01){ref-type="fig"}. The Regional and Central Ethics Committee at the Karolinska Institute approved the study. Informed consent was obtained from all subjects and at least one of their parents after the nature of the study had been fully explained to them.

![Exclusion procedure of (a) the clinical sample, and (b) the control sample.](psyp0051-0412-f1){#fig01}

Physiological Measurements
--------------------------

ETCO~2~, RR, and HR were measured continuously using an Air-Pas oxycapnograph (PBM, Stockholm, Sweden), a J&J Engineering I-330-C-2 physiological monitoring system (J&J Engineering, Poulsbo, WA), and cStress customized software (PBM). CO~2~ measured as a percentage in exhaled air was sampled from a nasal cannula (Ø = 5 mm) inserted 10 mm into the left nostril. ETCO~2~ was identified by an algorithm in the customized software as the peak of the CO~2~ concentration at the end of the exhalation phase. ETCO~2~ corresponds well to arterial pCO~2~ ([@b17]). RR was calculated as breaths per minute from CO~2~ fluctuations, counting the peaks per minute.

The electrocardiogram (ECG) was recorded from electrodes placed on the left and right wrist with a sampling rate of 1024 Hz. Interbeat intervals were calculated online using an R-wave peak detection algorithm and stored on a PC for offline editing and calculation of HRV indices. The ECG recording time was 4 min and was preceded by 15 min of rest. The subjects were sitting upright in silence breathing spontaneously. No body movements were allowed during the procedure. None of the subjects had clinical signs or symptoms of infectious disease. Use of tobacco (snuff and cigarettes) or intake of tea, coffee, and caffeine containing soft drinks or beta stimulant asthma medication was not allowed 1 h prior to the measurements. All the recorded signals were scanned manually offline for distortions due to movement and irregular or distorted breaths caused by talk, movements, sighs, coughs, or yawns. In the CO~2~ signal, each breath was checked to reach an end-tidal plateau and was otherwise removed. Discarded interbeat intervals were replaced using a cubic spline interpolation. The standard deviation of the interbeat intervals (SDNN) was used as a time domain measure of HRV reflecting all of the cyclic components responsible for variability in the period of recording. Fourier analysis was performed on de-trended data in which the variability distributes as a function of frequency. The high frequency power component (HF; 0.15--0.4 Hz) and the low frequency power component (LF; 0.04--0.15 Hz) were used as frequency domain measures of HRV. The HF, LF, and SDNN were calculated and then logarithmically transformed. This 4-min HRV registration has previously been shown to generate stable results in repeated measures 6 months later in the control sample, supporting that short registrations without standardized interventions can capture HRV differences of possible predictive and clinical value ([@b24]). We have previously published comparisons between HRV indices of the same samples ([@b25]), and these data are the basis for the current investigations on associations between autonomic regulation and respiratory parameters.

Self-Assessment Scales and Diagnostic Validation
------------------------------------------------

The Strengths and Difficulties Questionnaire (SDQ) is a widely used screening instrument for mental health problems in children and teenagers ([@b18]). It is made up of 25 statements regarding psychological symptoms and behaviors, forming five subscales: hyperactivity/ inattention, emotional symptoms, conduct problems, peer problems, and prosocial behaviors. In this study, only the emotional scale (SDQ-em) was used. The SDQ-em does not differentiate between anxiety and depressive problems but gives a score of emotional symptom severity. Acceptable psychometric properties for the self-report version of SDQ for adolescents have been shown in previous studies, and SDQ-em has been shown to have valid ability to differentiate cases of MDD and AD in this age group ([@b10]).

The DAWBA ([@b19]) is a frequently used internet-based structured interview compatible with the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). It focuses on current rather than lifetime problems.

Statistical Analyses
--------------------

Groups were compared in a two-tailed fashion, with the unpaired two-sample *t* test. Associations between the SDQ-em, ETCO~2~, RR, and HRV indices (HF, LF, and SDNN) were assessed by Pearson\'s product-moment correlations. HF, LF, and SDNN had positively skewed distributions and were therefore logarithmically transformed to obtain normal distributions. Three logistic regression analyses with ETCO~2~, RR, HRV, and HR as independent variables and group status (clinical vs. control) as dependent variable were conducted. The three analyses were identical except that the HRV index was exchanged including HF in Model 1, LF in Model 2, and SDNN in Model 3. The three HRV indices are all highly intercorrelated (all *r*s \> .8) and were therefore not entered together in one model due to multicollinearity. Probability levels of .05 or less were considered significant. Analyses were done in Statistica 11 (<http://www.statsoft.com>).

Results
=======

ETCO~2~, RR, and the emotional symptom severity, as measured by SDQ-em scores, differed significantly between the clinical sample and controls; that is, ETCO~2~ was lower, but RR and SDQ-em scores were higher in the clinical sample as compared with the controls (Table [1](#tbl1){ref-type="table"}). ETCO~2~, HR, and the three HRV indices (HF, LF, and SDNN), but not RR, were significant unique predictors of clinical status in the regression models (Table [2](#tbl2){ref-type="table"}). ETCO~2~ showed the largest unique contribution to the prediction followed by HRV and HR. The models correctly classified 84--87% of the cases.

###### 

Mean Values and Standard Deviations (SD) of the Emotional Symptom Severity Score, End-Tidal CO~2~, and Respiratory Rate for the Control and Clinical Sample

                Control sample   Clinical sample   Cohen\'s *d*   *t* value
  ------------- ---------------- ----------------- -------------- -------------------------------------------
  SDQ-em        3.7 (2.3)        7.3 (1.6)         1.8            −9.8[\*\*\*](#tf1-3){ref-type="table-fn"}
  ETCO~2~ (%)   4.8 (0.3)        4.2 (0.3)         2.0            10.8[\*\*\*](#tf1-3){ref-type="table-fn"}
  RR (BrPM)     14.9 (4.4)       16.4 (3.8)        0.4            −2.1[\*](#tf1-2){ref-type="table-fn"}

*Note.* SDQ-em = Strengths and Difficulties Questionnaire emotional subscale; ETCO~2~ = end-tidal CO~2~; RR = respiratory rate; BrPM = breaths per minute.

*p* \< .05.

*p* \< .001.

###### 

Three Logistic Regression Models with Group Status (Clinical vs. Control) as Dependent Variable

  *n* = 112        Estimate   Odds ratio   *p*        AIC    Log odds ratio for classification of cases
  ---------------- ---------- ------------ ---------- ------ --------------------------------------------
  Model 1 (HF)                                        82.2   3.90
   ETCO~2~         6.36       578.54       \< .0001          
   RR              0.00       1.00         .96               
   HR              0.11       1.12         .004              
   HF              1.04       2.84         .01               
  Model 2 (LF)                                        85.1   3.44
   ETCO~2~         6.34       566.90       \< .0001          
   RR              0.02       1.02         .83               
   HR              0.08       1.09         .02               
   LF              0.81       2.25         .04               
  Model 3 (SDNN)                                      79.4   3.44
   ETCO~2~         6.30       546.30       \< .0001          
   RR              0.02       1.02         .81               
   HR              0.12       1.13         .002              
   SDNN            3.36       28.89        .004              

*Note.* The three models exchange heart rate variability (HRV) index as independent variable so that Model 1 includes HF; Model 2, LF; and Model 3, SDNN. End-tidal CO~2~ (ETCO~2~), respiratory rate (RR), and heart rate (HR) are included as independent measures in all models. Akaike information criterion (AIC) and log odds ratio for classification of cases are reported as measures of the relative quality of the models.

SDQ-em scores showed significant correlations to RR and ETCO~2~ in the combined group of clinical and control subjects, but not when the clinical and control samples were analyzed separately (Table [3](#tbl3){ref-type="table"}). All indices of HRV (HF, LF, and SDNN) correlated significantly with ETCO~2~ and RR (inverse) in the total group. In the clinical sample, only a significant inverse correlation between RR and LF was found. In the control sample, significant inverse correlations were found between RR and all the HRV indices. There were no significant correlations between ETCO~2~ and any HRV measures in the clinical or in the control samples when analyzed separately (Table [2](#tbl2){ref-type="table"}).

###### 

Pearson Product-Moment Correlation Coefficients (rs) Showing the Associations between the Emotional Symptom Severity Score and Heart Rate Variability on One Side and End-Tidal CO~2~ and Respiratory Rate on the Other

                                                 Pearson\'s *r*                              
  ---------------------------------------------- ------------------------------------------- -------------------------------------------
  SDQ-em (*n*)                                                                               
   Total (125)                                   −.44[\*\*\*](#tf3-5){ref-type="table-fn"}   .25[\*\*](#tf3-4){ref-type="table-fn"}
   Controls (62)                                 −.09                                        .23
   Clinical group (63)                           .24                                         .08
  HF (*n*)                                                                                   
   Total (112[a](#tf3-2){ref-type="table-fn"})   .23[\*](#tf3-3){ref-type="table-fn"}        −.24[\*](#tf3-3){ref-type="table-fn"}
   Controls (53)                                 .15                                         −.43[\*\*](#tf3-4){ref-type="table-fn"}
   Clinical group (59)                           −.01                                        .02
  LF (*n*)                                                                                   
   Total (112[a](#tf3-2){ref-type="table-fn"})   .19[\*](#tf3-3){ref-type="table-fn"}        −.44[\*\*\*](#tf3-5){ref-type="table-fn"}
   Controls (53)                                 −.09                                        −.53[\*\*\*](#tf3-5){ref-type="table-fn"}
   Clinical group (59)                           .12                                         −.30[\*](#tf3-3){ref-type="table-fn"}
  SDNN (*n*)                                                                                 
   Total (112[a](#tf3-2){ref-type="table-fn"})   .22[\*](#tf3-3){ref-type="table-fn"}        −.33[\*\*\*](#tf3-5){ref-type="table-fn"}
   Controls (53)                                 −.06                                        −.48[\*\*\*](#tf3-5){ref-type="table-fn"}
   Clinical group (59)                           .11                                         −.11

*Note.* ETCO~2~ = end-tidal CO~2~; RR = respiratory rate; SDQ-em = Strengths and Difficulties Questionnaire emotional subscale; HF = high frequency; LF = low frequency; SDNN = standard deviation of the interbeat intervals.

13 subjects (10 in the clinical group and 3 in the control group) had distorted HR data.

*p* \< .05.

*p* \< .01.

*p* \< .001.

In the clinical sample, ETCO~2~ and RR did not differ significantly between the subgroup taking SSRIs as compared with the subgroup without SSRI medication (*n*s = 21 and 40; both *p*s \> .4). Hormonal contraceptives were more frequently used in the clinical sample compared with controls (21 of 62 compared with 5 of 63, χ^2^ = 12.5, *p* \< .001). The significant differences between the clinical and control samples regarding ETCO~2~ and RR remained unchanged when subjects using hormonal contraceptives were excluded (ETCO~2~: *t* = 9.5, *p* \< .001; RR: *t* = 2.5, *p* \< .05; *n*s = 41 and 57). Information about contraceptives was missing from one girl in the control sample.

Discussion
==========

The main finding of this study is that the clinical sample, consisting of adolescent girls with a diagnosis of MDD and/or AD, showed significantly lower ETCO~2~ and higher RR compared with the sample of healthy, age-matched controls. ETCO~2~ showed the largest unique contribution to the prediction of clinical group status (i.e., a diagnosis of MDD and/or AD). HR and HRV also significantly predicted clinical status but to a lesser degree, while RR did not. ETCO~2~ showed the largest difference between the clinical and control samples on all included measures (Cohen\'s *d* = 2.0), and RR showed only a small difference (Cohen\'s *d* = 0.4). The mean ETCO~2~ value for the clinical sample was below the suggested normal reference range (ETCO~2~ = 4.6--6.0%) and close to the cut-off suggested for hyperventilation syndrome (ETCO~2~ ≤ 4.0%; [@b6]; [@b17]; [@b60]). The mean ETCO~2~ value for the control sample was within the normal range, and the mean RR was within the normal range in both groups. Significant correlations between emotional symptom severity, as measured with SDQ-em, and both ETCO~2~ and RR, respectively, were found in the total sample. No correlations between these variables were found when each sample was analyzed separately. This is probably due to the limited ranges observed for the symptom severity and physiological measures.

The regression analyses presented above also confirm the previously reported findings that all measured HRV indices (i.e., HF, LF, and SDNN) were significantly lower in the clinical sample compared with healthy controls, the effect sizes ranging from Cohen\'s *d =* 0.53 to 0.60 ([@b25]). These new analyses expand on the previous findings by showing that the results remain even when controlling for RR, ETCO~2~, and HR. No significant difference of HR has been found between the clinical sample (73.2 beats per minute) and the controls (76.2 beats per minute). For detailed analyses of HRV, we refer to our previous publication ([@b25]).

Significant correlations between autonomic regulation measured by LF, HF, and SDNN and RR were found in the total group and in the control sample, but in the clinical sample only between LF and RR. The most reliably described heart rate periodicities of HRV are the HF and LF domains. HF includes the spontaneous breathing rate (i.e., RSA), and LF is assumed to be related to the endogenous rhythm of blood pressure regulation via the baroreceptors and spontaneous vasomotor activity ([@b45]). One may speculate that an impairment of autonomic regulation is part of the pathophysiology of depression and anxiety that causes a decoupling between RR and HRV ([@b16]; [@b39]; [@b58]). This would result in a diminished RSA (HF) as well as in a weaker relationship between RR and HF in the clinical sample. LF, on the other hand, is based on slower endogenous rhythms and is not as sensitive to changes of RR. The association between HRV and RR in the control sample is well documented in studies on adults and is believed to be related to longer exhalation time, which allows for a more extensive vagal cholinergic influence on the heart ([@b7]; [@b46]). We did not find any effect of SSRIs or hormonal contraceptives on respiratory parameters.

Our findings imply a difference in ETCO~2~ (but not in RR) between the groups that may be of clinical relevance. The finding that ETCO~2~ is the strongest and a unique predictor of clinical status (stronger than HR and HRV) is new and suggests that respiratory alkalosis is related to emotional dysregulation in adolescent girls. Changes of pCO~2~ have an effect on cerebral blood flow ([@b56]) and cause alterations in the chemoreception in the brain stem ([@b3]; [@b27]; [@b29]; [@b48]), which may be possible mechanisms explaining the relationship between ETCO~2~ and emotional symptoms. One may also hypothesize that chronic changes of ETCO~2~ impact the allostatic load and that chronic emotional distress leads to increased RR and hyperventilation, which decreases autonomic regulation and causes respiratory alkalosis, in turn leading to increased emotional distress.

Our findings have to be regarded with several limitations in mind: (a) the cross-sectional design does not allow for any conclusions on causality and does not exclude possible confounding variables; (b) tidal volume was not measured, and consequently RSA could not be calculated taking it into account ([@b22]); (c) respiratory rate was derived from the raw CO~2~ signal instead of being measured directly from flow or respiratory movement recordings; (d) the significant correlations between ETCO~2~ and HRV that were shown for the total group may be dependent on the documented group differences in both variables; and (e) we did not have information on when in the menstrual cycle the physiological data were obtained, which would have been valuable because hormonal factors related to the menstrual cycle are known to influence breathing patterns and affect ETCO~2~ ([@b14]).

Several studies have shown that regular practice of breathing techniques substantially reduced chemoreflex sensitivity ([@b50]) and reduced oxidative stress ([@b49]) and depressive symptoms ([@b55]). Unfortunately, these studies include a variety of different breathing techniques making it difficult to identify the possible active mechanism. Studies with better controlled forms of breathing training have been performed, especially targeting patients with panic disorder. Both voluntary hyper- and hypoventilation interventions have shown beneficial results, thus leading to the conclusion that the reduction of symptoms were not related to changes in ETCO~2~ ([@b31]; [@b42]; [@b62]). A few small studies on respiratory biofeedback with focus on the RSA have indicated effects on anxious and depressive symptoms ([@b44]; [@b51]). Future intervention studies may evaluate breathing practices aided by respiratory biofeedback as treatment in the increasing population of adolescent girls with emotional disorders.

In conclusion, adolescent girls with clinical depression and/or anxiety show signs of hyperventilation evidenced by significantly lower ETCO~2~ compared with healthy controls. This suggests that emotional dysregulation is related to hyperventilation in adolescent girls and that regular breathing training may be relevant to study as an intervention for emotional disorders in this age group.
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